Question 1

What is the current share price of Cohance Lifesciences Ltd (COHANCE)?

Accepted Answer

The current share price of Cohance Lifesciences Ltd (COHANCE) is ₹431.1. Today, the stock has gained by ₹5.80 (1.36%), trading in a range of ₹426 to ₹448. The stock opened at ₹427.8 with a trading volume of 15,92,037 shares.

Question 2

Is Cohance Lifesciences Ltd stock a good investment for long-term?

Accepted Answer

Cohance Lifesciences Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹0 crores, P/E ratio of 91.07, ROE of 3.84%, and ROCE of 14.90%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.

Question 3

What is the 52-week high and low price of Cohance Lifesciences Ltd stock?

Accepted Answer

The 52-week high price of Cohance Lifesciences Ltd (COHANCE) is ₹1,121.15, while the 52-week low is ₹266.7. Currently trading at ₹431.1, the stock is 19.2% away from its 52-week low and 61.5% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.

Question 4

Should I buy Cohance Lifesciences Ltd stock at the current price?

Accepted Answer

Whether to buy Cohance Lifesciences Ltd stock at ₹431.1 depends on multiple factors. The stock is currently trading with a P/E ratio of 91.07 and P/B ratio of N/A. Today's performance shows a gain of 1.36%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.

Question 5

What is the dividend yield of Cohance Lifesciences Ltd and when is the next dividend?

Accepted Answer

Cohance Lifesciences Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹431.1, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.

Question 6

What are the key financial ratios and metrics of Cohance Lifesciences Ltd?

Accepted Answer

Cohance Lifesciences Ltd's key financial metrics include: P/E Ratio: 91.07, P/B Ratio: N/A, ROE: 3.84%, ROCE: 14.90%, Dividend Yield: 0.00%, EPS: ₹4.67, Book Value: ₹102.03, Debt-to-Equity: 9.93, and Current Ratio: N/A. The company's market cap stands at ₹0 crores. These metrics help evaluate the company's valuation, profitability, and financial health.

Question 7

How is Cohance Lifesciences Ltd stock performing today in the market?

Accepted Answer

Cohance Lifesciences Ltd stock opened at ₹427.8 and is currently trading at ₹431.1, showing a gain of ₹5.80 (1.36%). The intraday high is ₹448 and low is ₹426. The trading volume stands at 15,92,037 shares, indicating strong market participation today.

Question 8

What is the P/E ratio of Cohance Lifesciences Ltd and what does it indicate?

Accepted Answer

Cohance Lifesciences Ltd has a Price-to-Earnings (P/E) ratio of 91.07, which means investors are willing to pay ₹91.07 for every ₹1 of earnings. With an EPS of ₹4.67, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.

Question 9

What is the market capitalization of Cohance Lifesciences Ltd?

Accepted Answer

Cohance Lifesciences Ltd has a market capitalization of ₹0 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹431.1) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.

Question 10

What is the book value and P/B ratio of Cohance Lifesciences Ltd?

Accepted Answer

Cohance Lifesciences Ltd has a book value of ₹102.03 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹431.1, which is 322.5% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.

Question 11

What is the ROE and ROCE of Cohance Lifesciences Ltd?

Accepted Answer

Cohance Lifesciences Ltd has a Return on Equity (ROE) of 3.84% and Return on Capital Employed (ROCE) of 14.90%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.

Question 12

Which sector and industry does Cohance Lifesciences Ltd belong to?

Accepted Answer

Cohance Lifesciences Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.

Question 13

What is the debt-to-equity ratio of Cohance Lifesciences Ltd?

Accepted Answer

Cohance Lifesciences Ltd has a debt-to-equity ratio of 9.93, which measures the company's financial leverage by comparing total debt to shareholders' equity. A ratio above 2 indicates high leverage and potentially higher financial risk. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.

Question 14

What is the EPS (Earnings Per Share) of Cohance Lifesciences Ltd?

Accepted Answer

Cohance Lifesciences Ltd has an Earnings Per Share (EPS) of ₹4.67, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹431.1 and P/E ratio of 91.07, investors are paying 91.07 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.

Question 15

What is the sales and profit growth of Cohance Lifesciences Ltd?

Accepted Answer

Cohance Lifesciences Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.

Question 16

What is the current ratio of Cohance Lifesciences Ltd and what does it mean?

Accepted Answer

Cohance Lifesciences Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.

Question 17

How to analyze Cohance Lifesciences Ltd stock for investment?

Accepted Answer

To analyze Cohance Lifesciences Ltd stock, consider: 1) Fundamental Analysis - Review P/E (91.07), ROE (3.84%), debt-to-equity (9.93), and growth rates. 2) Technical Analysis - Check 52-week range (₹266.70 - ₹1121.15), moving averages, and chart patterns. 3) Valuation - Compare current price (₹431.10) with book value (₹102.03) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.

Question 18

What is the face value of Cohance Lifesciences Ltd share?

Accepted Answer

The face value (or par value) of Cohance Lifesciences Ltd share is ₹1.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹431.1 is 43010x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.

Question 19

What are the risks of investing in Cohance Lifesciences Ltd stock?

Accepted Answer

Investing in Cohance Lifesciences Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹266.70 - ₹1121.15). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 9.93 indicates leverage. 4) Liquidity Risk - Based on trading volume of 15,92,037 shares. 5) Valuation Risk - P/E of 91.07 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.

Question 20

How does Cohance Lifesciences Ltd compare with its industry peers?

Accepted Answer

Cohance Lifesciences Ltd operates in the industry with key metrics: P/E ratio of 91.07, ROE of 3.84%, market cap of ₹0 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 9.93), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.

Question 21

What is the target price for Cohance Lifesciences Ltd stock?

Accepted Answer

Target prices for Cohance Lifesciences Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹431.1, with a 52-week range of ₹266.70 to ₹1121.15. Based on fundamentals like P/E (91.07), ROE (3.84%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.

Question 22

When should I sell Cohance Lifesciences Ltd stock?

Accepted Answer

Consider selling Cohance Lifesciences Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹431.10. 2) Fundamental Deterioration - Declining ROE (currently 3.84%), increasing debt (D/E: 9.93), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.

Question 23

What are the tax implications of investing in Cohance Lifesciences Ltd stock?

Accepted Answer

Tax implications for Cohance Lifesciences Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.

Question 24

Is Cohance Lifesciences Ltd stock good for SIP (Systematic Investment Plan)?

Accepted Answer

Cohance Lifesciences Ltd can be considered for a Systematic Investment Plan (SIP) by long-term investors who want rupee-cost-averaging exposure to the sector sector. With a 52-week range of ₹266.7 to ₹1,121.15, monthly SIPs smooth out price volatility. Evaluate the company's ROE of 3.84%, profit growth of N/A% and debt-to-equity of 9.93 before committing — SIPs work best when underlying fundamentals are stable. Consult a SEBI-registered advisor for a personalised plan.

Question 25

When is the next dividend ex-date for Cohance Lifesciences Ltd?

Accepted Answer

Cohance Lifesciences Ltd has a current dividend yield of 0.00% on a market price of ₹431.1. The next ex-dividend date is announced by the company through corporate filings on the BSE and NSE. Check the Corporate Actions section on this page for the most recent declared dividends, ex-dates, record dates and the full historical pay-out pattern.

Question 26

What is the latest shareholding pattern of Cohance Lifesciences Ltd?

Accepted Answer

Cohance Lifesciences Ltd's most recent quarterly shareholding pattern is displayed in the Ownership section above. It covers the promoter holding, foreign institutional investor (FII) stake, domestic institutional investor (DII) stake and public float — each tracked quarter-on-quarter so trends in institutional buying or selling are visible. Disclosed institutional holders are listed separately below the cohort breakdown.

Question 27

What are the support and resistance levels for Cohance Lifesciences Ltd stock?

Accepted Answer

Daily support and resistance levels for Cohance Lifesciences Ltd are computed live from the latest session's high (₹448), low (₹426) and close (₹431.1). They are listed in the Technicals section as classical pivot points (R1/R2/R3 above and S1/S2/S3 below the pivot) along with the Central Pivot Range (CPR) — useful reference levels for intraday and short-term traders.

Question 28

Has Cohance Lifesciences Ltd ever issued bonus shares or done a stock split?

Accepted Answer

The full history of Cohance Lifesciences Ltd bonus issues, stock splits and dividend declarations is in the Corporate Actions section above. Each event is listed with its announce date, record date and ratio, so investors can verify every capital-structure change Cohance Lifesciences Ltd has made over time on the NSE and BSE.

Question 29

How is Cohance Lifesciences Ltd performing compared to its sector and peers?

Accepted Answer

Cohance Lifesciences Ltd operates in the industry within the sector sector and trades at a P/E of 91.07 with an ROE of 3.84% and ROCE of 14.90%. Compare these to same-sector listed peers in the Peer Comparison section above to see whether Cohance Lifesciences Ltd is leading or lagging on valuation, capital efficiency and growth.

Question 30

What is the promoter holding in Cohance Lifesciences Ltd and is it increasing?

Accepted Answer

The latest promoter holding in Cohance Lifesciences Ltd is shown in the Ownership section, along with the quarter-on-quarter change in basis points. Rising promoter holding usually signals confidence in the business outlook, while sustained selling — especially by promoters who founded or run the company — is a signal worth investigating in the subsequent filings.

Question 31

Can I buy Cohance Lifesciences Ltd shares on NSE and BSE?

Accepted Answer

Yes — Cohance Lifesciences Ltd (COHANCE) is listed and actively traded on both NSE and BSE. You can buy shares through any SEBI-registered stockbroker during market hours (09:15–15:30 IST on trading days). The current market price, today's intraday range and the live quote are at the top of this page; settlement is T+1 for Indian equities.

Level	Price (₹)	Distance	% Δ
R4	488.07	+56.97	+13.21%
R3	466.07	+34.97	+8.11%
R2	457.03	+25.93	+6.02%
R1	444.07	+12.97	+3.01%
PIVOT	435.03	3.93	0.91%
CURRENT	431.10	—	—
S1	378.07	-53.03	-12.30%
S2	400.07	-31.03	-7.20%
S3	413.03	-18.07	-4.19%
S4	422.07	-9.03	-2.10%

Insider	Category	Txn Date	Action	Quantity	Value (₹)	Price
Jusmiral Holdings Limited	Insider	09 May 2025	buy	+12.65 Cr	₹12.65 Cr	₹1.00
Dr. Venkata Naga Kali Vara Prasada Raju Vetukuri	Insider	09 May 2025	buy	+7.13 L	₹7.13 L	₹1.00

Cohance Lifesciences

Cohance Lifesciences Ltd valuation: P/E, P/B and sector benchmarks.

Valuation

Profitability

Growth

Financial Health

Cohance Lifesciences Ltd financials: P&L, balance sheet, cash flow, ratios.

Cohance Lifesciences segment analysis: revenue and profit mix.

Segment-wise Financial Analysis

Cohance Lifesciences Ltd investment thesis: bull case, bear case, and the flip lines.

What you're getting.

What can break it.

What would change my mind.

Cohance shareholding pattern: promoters, FII, DII and public.

Shareholding Pattern

Cohance Lifesciences Ltd peer comparison — same-sector benchmarks.

Quick Compare

Peer Comparison

Cohance Lifesciences Ltd technical analysis: indicators, pivots and CPR.

Pivot points

Pivot levels · Classic

Cohance Lifesciences Ltd delivery volume — last 20 sessions of conviction.

Cohance Lifesciences announcements: results, concalls, ratings, M&A.

Cohance Lifesciences insider trading: promoter and management activity.

Cohance Lifesciences dividend history, splits and bonus issues.

About Cohance Lifesciences Ltd: business, sector, key facts.

Cohance Lifesciences Ltd

Questions investors ask about Cohance Lifesciences Ltd (COHANCE).

Company Name
Aarey Drugs & Pharmaceuticals Ltd
Aarti Drugs Ltd
Aarti Pharmalabs Ltd
Ajanta Pharma Ltd
Akums Drugs & Pharmaceuticals Ltd
Albert David Ltd
Alivus Life Sciences Ltd
Alkem Laboratories Ltd
Alpa Laboratories Ltd
Amrutanjan Health Care Ltd
Alembic Pharmaceuticals Ltd
Astrazeneca Pharma India Ltd
Aurobindo Pharma Ltd
Bafna Pharmaceuticals Ltd
Bajaj Healthcare Ltd
Bal Pharma Ltd
Biocon Ltd
Biofil Chemicals & Pharmaceuticals Ltd
Bliss GVS Pharma Ltd
Blue Jet Healthcare Ltd
Brooks Laboratories Ltd
Caplin Point Laboratories Ltd
Cipla Ltd
Cohance Lifesciences LtdCurrent Stock
Concord Biotech Ltd
Dishman Carbogen Amcis Ltd
Divis Laboratories Ltd
Dr Reddys Laboratories Ltd
Emcure Pharmaceuticals Ltd
ERIS Lifesciences Ltd
FDC Ltd
Gland Pharma Ltd
Glaxosmithkline Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd
Granules India Ltd
Gufic BioSciences Ltd
Haleos Labs Limited
Hester Biosciences Ltd
Hikal Ltd
Indoco Remedies Ltd